Magenta Therapeutics, Inc. (MGTA): Price and Financial Metrics
GET POWR RATINGS... FREE!
MGTA Stock Price Chart Interactive Chart >
MGTA Price/Volume Stats
| Current price | $0.79 | 52-week high | $3.49 |
| Prev. close | $0.77 | 52-week low | $0.32 |
| Day low | $0.76 | Volume | 274,900 |
| Day high | $0.80 | Avg. volume | 1,658,279 |
| 50-day MA | $0.74 | Dividend yield | N/A |
| 200-day MA | $1.18 | Market Cap | 48.19M |
Magenta Therapeutics, Inc. (MGTA) Company Bio
Magenta Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Latest MGTA News From Around the Web
Below are the latest news stories about MAGENTA THERAPEUTICS INC that investors may wish to consider to help them evaluate MGTA as an investment opportunity.
Magenta adopts stockholder rights plan to ward off unwanted bids
|
Magenta Therapeutics Adopts Limited Duration Stockholder Rights PlanCAMBRIDGE, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (Nasdaq: MGTA) (“Magenta” or the “Company”) today announced that its Board of Directors (the “Board”) has unanimously adopted a limited duration stockholder rights plan (the “Rights Plan”). The Rights Plan will give the Board sufficient time to conduct its previously announced comprehensive review of strategic alternatives focused on maximizing shareholder value. The Rights Plan has been adopted in order to protect t |
The Zacks Analyst Blog Highlights Blue Bird, Comfort Systems, Salesforce, Deckers Outdoor and Magenta TherapeuticsBlue Bird, Comfort Systems, Salesforce, Deckers Outdoor and Magenta Therapeutics are included in this Analyst Blog. |
Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
On eve of shutdown, Cambridge biotech loses 84% of staff, including 5 execsIn the midst of exploring a sale, Magenta Therapeutics Inc. is laying off the vast majority of its staff, including five executives. |
MGTA Price Returns
| 1-mo | -1.25% |
| 3-mo | 100.00% |
| 6-mo | -42.75% |
| 1-year | -73.49% |
| 3-year | -87.40% |
| 5-year | N/A |
| YTD | 100.00% |
| 2022 | -91.08% |
| 2021 | -43.49% |
| 2020 | -48.28% |
| 2019 | 165.96% |
| 2018 | N/A |
Loading social stream, please wait...